Two new companies have moved into the BioVentureHub at AstraZeneca Gothenburg, bringing the total to 17 companies and 1 academic group.
The newcomers are: Promimic, developers of an innovative implant surface that mimics living bone tissue, and TATAA Biocenter, experts in nucleic acid and protein analyses.
Magnus Björsne, AstraZeneca’s Executive Director for the BioVentureHub (BVH), is excited to welcome the new companies to the Gothenburg site: “Promimic and TATAA Biocenter are terrific additions to the BioVentureHub. They lead scientific innovation in their respective fields and add new capabilities, ideas and perspectives into the hub mix.”
AstraZeneca established the BVH in 2014 to stimulate open and collaborative innovation and to strengthen competitiveness in the Scandinavian life sciences. Supporting the AstraZeneca Gothenburg site vision to be one of the best R&D sites in the world, the BVH gives emerging biotech/medtech companies and academic groups a unique opportunity to co-locate and interact with AstraZeneca’s scientists and state-of-the-art lab facilities and infrastructure, and with each other.
Promimic has moved into the BVH to further develop its innovative HAnano Surface, which represents a new generation of implant surfaces based on synthetic bone minerals.
“We started our journey of growth last year. To ensure that we can continue to satisfy our customers and to stay at the forefront of product innovation, we needed to upgrade our facilities. Moving into the BioVentureHub and having access to the AstraZeneca labs and infrastructure provides us with the ideal foundation on which we can build the future growth and success of our company,” says Ulf Brogren, CEO of Promimic.
TATAA Biocenter, located in Göteborg (Sweden), Prague (Czech Republic) and Saarbrucken, (Germany), has opened an R&D unit in the BioVentureHub. The unit is led by Dr Robert Sjöback, and will develop TATAA’s novel technology for exceedingly sensitive and specific analysis of microRNAs, as well as quality control products for molecular analyses.
”As we develop innovative methods and products, it is extremely valuable for our R&D team to be embedded amongst interested and knowledgeable potential users that provide input during the development stage and then support our testing and validation”, says Mikael Kubista, CEO and founder of TATAA Biocenter.
About AstraZeneca BioVentureHub
AstraZeneca established the BioVentureHub in 2014 as an open innovation ecosystem to further strengthen competitiveness and dynamism in the Scandinavian life science industry. Based on an innovative public-private partnership model and located at the heart of AstraZeneca Gothenburg, the BioVenturehub gives emerging biotech/medtech companies and academic groups from Sweden and abroad a unique opportunity to co-locate with - and tap into - the power of AstraZeneca’s world-class scientists and state-of-the-art lab facilities and infrastructure, and with each other. www.azbioventurehub.com
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
Promimic has developed a process that makes it possible to modify all types of implant materials and geometries with a nanometer-thin surface of synthetic bone minerals; HAnano Surface. It is based on the substance hydroxyapatite (HA)., which by size, shape, structure and chemistry mimics the living bone tissue. The HAnanoSurface is licensed to dental and orthopaedic implants companies. Promimic is a spin-off company based on research from Chalmers University of Technology. For more information about the company, please visit the web page: www.promimic.com
About TATAA Biocenter
TATAA Biocenter is the world’s largest organizer of hands-on training in molecular analyses, Europe’s leading provider of nucleic acid analysis services, and Scandinavia’s most comprehensive distributor of products for nucleic acids analyses. Through its laboratories in Göteborg, Sweden, and Prague, Czech Republic, and sales office in Saarbrucken, Germany, TATAA Biocenter supports its clients with products for full range of nucleic acid and protein analyses and services in compliance with ISO17025 standard. In 2013, TATAA Biocenter was presented the Frost & Sullivan Award for Customer Value Leadership as Best-in-Class Services for Analyzing Genetic Material. In 2015, TATAA separated its consumer diagnostic service business into Life Genomics AB. For more information visit www.tataa.com
Jacob Lund, AstraZeneca Sweden: +46 8-553 260 20/+ 46 72-560 2157
= = =
AstraZeneca är ett globalt, innovativt bioläkemedelsföretag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom områdena hjärta/kärl, metabolism, andningsvägar, inflammation, autoimmunitet, cancer, infektion och neurovetenskap. AstraZeneca är verksamt i över 100 länder och våra innovativa läkemedel används av miljontals patienter världen över.